ZWI 002
Alternative Names: ZWI-002Latest Information Update: 01 Mar 2024
At a glance
- Originator ZWI Therapeutics
- Class Drug conjugates; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 22 Feb 2024 ZWI 002 is available for licensing as of 22 Mar 2024. https://zwitx.com/home
- 22 Feb 2024 ZWI Therapeutics has patent protection for ZWI technology (ZWI Therapeutics website, February 2024)
- 22 Feb 2024 Early research in Unspecified in USA (Parenteral) prior to February 2024 (ZWI Therapeutics pipeline, February 2024)